Introduction {#section1-2050313X17720101}
============

Pantothenate-kinase-associated neurodegeneration (PKAN) is the most common cause of neurodegeneration with brain iron accumulation (NBIA).^[@bibr1-2050313X17720101]^ It is caused by mutations in the panthonate kinase-2 gene (*PANK2*) and it is inherited in an autosomal recessive manner.^[@bibr2-2050313X17720101]^ The classical form of the disease is characterized by childhood onset and relatively rapid progression; however, approximately 25% of patients have an atypical form, with onset in the second or third decade, a variable rate of progression and the presence of psychiatric symptoms, seizures and focal dystonia.^[@bibr1-2050313X17720101],[@bibr2-2050313X17720101]^ Here, we report the first Greek compound heterozygote patient with atypical PKAN, carrying a novel mutation.

Clinical report {#section2-2050313X17720101}
===============

The patient is a 25-year-old male, offspring of a non-consanguineous marriage. At age 22, he had to interrupt his studies on physics due to dystonic right arm movements resulting in writing difficulties. He gradually developed orobuccal dystonia and dysarthria. The patient's Burke--Fahn--Marsden Dystonia Rating Scale (BFMDRS) score was 12.^[@bibr3-2050313X17720101]^ He exhibited mild cogwheel rigidity, reflexes were brisk and plantar responses were indifferent, but neurological examination was otherwise unremarkable. Motor function was evaluated with the Movement Disorder Society--Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), yielding a total score of 6 points.^[@bibr4-2050313X17720101]^ Ophthalmologic evaluation showed absence of Kayser--Fleischer rings, optic atrophy or pigmentary retinopathy. Peripheral blood acanthocytosis was not observed. Routine laboratory evaluation was normal. Neuropsychological evaluation revealed no cognitive decline or behavioral/psychiatric symptoms (see [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/2050313X17720101)). Brain imaging revealed the "eye-of-the-tiger" sign ([Figure 1(a)](#fig1-2050313X17720101){ref-type="fig"} and [(b)](#fig1-2050313X17720101){ref-type="fig"}). There is no family history. His mother (58 years) is asymptomatic and his father died of lung cancer at age 54. A trial with L-dopa, up to 750 mg/day, had no effect. Orphenadrin (150 mg daily) had an effect that was modest at best and the patient preferred discontinuation due to significant anticholinergic side effects.

![(a, b) Magnetic resonance imaging showing bilateral peripheral hypointensity in the globi pallidi with a central focus of gliosis, called as "eye-of-the-tiger" sign; (c) restriction fragment patterns of PCR products illustrating the alleles observed in loci c.1424 and c.1583.\
P: patient; Mo: patient's mother; HC: healthy control; M: molecular weight marker.](10.1177_2050313X17720101-fig1){#fig1-2050313X17720101}

Genetic analysis {#section3-2050313X17720101}
================

Blood samples for total DNA extraction were obtained from the patient and his mother after informed consent. The seven exons of PANK2 gene, including the exon/intron boundaries, were sequenced in the patient's DNA sample in GENetic DIAgnostic Network (GENDIA, Emiel Vloorsstraat 9, B 2020 Antwerp, Belgium). Two combined heterozygous mutations were detected, namely, p.Met475Thr (c.1424T\>C) in exon 5, and p.Thr528Met (c.1583C\>T) in exon 6 of PANK2.

Molecular detection of either mutation in the PANK2 gene of the patient, his mother and 100 healthy controls of Greek origin, aged 35--57 years, was performed by restriction fragment length polymorphism typing. This involved a combination of polymerase chain reaction (PCR) amplification and digestion with a specific restriction endonuclease that distinguished the normal and the mutant alleles followed by agarose gel electrophoresis analysis. For c.1424T\>C in exon 5, primers 5A (forward): 5′-GTTCTGTTGGGCTTTGTTGCTG-3′ and 5B (reverse): 5′-CACACATTCTTGCTATTGAGCC-3′ were used. The generated PCR product of 172 bp was cleaved by restriction enzyme NlaIII into two fragments of 100 and 72 bp only if the normal T allele was present. For c.1583C\>T in exon 6, primers 6A (forward): 5′-CATTAACCAGGTGGTATTTGTTGG-3′ and 6B (reverse): 5′-AGTGCTTTCAACTGCCCCTTG-3′ were used. The generated PCR product of 108 bp was cleaved by restriction enzyme PvuI into two fragments of 60 and 48 bp only if the normal C allele was present.

Restriction enzyme analysis verified that the patient had two mutations in compound heterozygosity: c.1424T\>C (p.M475T) and c.1583C\>T (p.T528M), at exons 5 and 6, respectively ([Figure 1(c)](#fig1-2050313X17720101){ref-type="fig"}). Mutation c.1583T\>C has been previously reported in PKAN patients and was absent in the patient's mother and 100 healthy Greeks (n = 200 PANK2 genes). However, the mother was a heterozygous carrier of the novel variant c.1424T\>C, which was absent in 100 healthy Greeks (n = 200 PANK2 genes), therefore, it seems that it is not a single nucleotide polymorphism but a novel mutation not previously described in PANK patients.

This novel c.1424T\>C mutation is not listed in the NHLBI Exome Variant database that contains many thousands of alleles.^[@bibr5-2050313X17720101]^ It is a missense mutation that results in the substitution of a methionine by a threonine on position 475 of the resulting protein (p.Met475Thr). In silico prediction by SIFT ("Sorting Tolerant From Intolerant," <http://sift.jcvi.org/>),^[@bibr6-2050313X17720101]^ PolyPhen-2 (Polymorphism Phenotyping version 2, <http://genetics.bwh.harvard.edu/pph2/>)^[@bibr7-2050313X17720101]^ and Mutation Taster (<http://www.mutationtaster.org/>)^[@bibr8-2050313X17720101]^ suggests pathogenicity (deleterious, probably damaging and disease-causing, respectively). Based on all the above-mentioned findings, the patient with the atypical PKAN had two disease-causing mutations in PANK2 gene in combined heterozygosity.

Discussion {#section4-2050313X17720101}
==========

One of the mutations observed in our patient (p.T528M) is already known as pathogenic, and it has been suggested to be the second most common *PANK2* mutation.^[@bibr9-2050313X17720101]^ The other (p.M475T), to the best of our knowledge, has never been described before. It was absent in 100 healthy Greeks (n = 200 *PANK2* genes), therefore, it is not a single nucleotide polymorphism, but a novel missense mutation and in silico prediction suggests pathogenicity. Although we have not determined the activity of pantothenate kinase 2 in our patient, the atypical form of the disease is usually associated with missense mutations preserving residual enzymatic activity.^[@bibr10-2050313X17720101]^ Furthermore, a catalytic defect is not obligatory for pathogenesis, since in the p.T528M and some other mutations, enzymatic activity is comparable to this of the wild type protein.^[@bibr9-2050313X17720101]^

In conclusion, we report a novel *PANK2* mutation in a compound heterozygote patient with atypical PKAN. Compound heterozygotes have been described with atypical PKAN.^[@bibr11-2050313X17720101][@bibr12-2050313X17720101]--[@bibr13-2050313X17720101]^ Interestingly, an atypical Cypriot PKAN case had a more severe extrapyramidal phenotype with respect to this one seen in our case.^[@bibr14-2050313X17720101]^ However, since genotype--phenotype correlation is limited,^[@bibr10-2050313X17720101]^ further studies are required to elucidate whether such a genotype tends to be associated with the atypical form of the disease.
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